Melgar, Cresencia S.
HRN: 18-31-23 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/08/2022
CIPROFLOXACIN 500MG (TAB)
11/08/2022
11/15/2022
PO
500mg
BID
Acute Pyelonephritis; T/C Adverse Drug Reaction To Ceftri
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes